Covance

Douglas M. Fast, Ph.D. has joined Covance as scientific director Bioanalytical Services. Dr. Fast has more than 16 years of drug development industry experience, including bioanalytical assay development, validation and sample assays for non-clinical and clinical studies. Dr. Fast will lead the North American staff scientist and principal investigator teams for the company’s small molecule bioanalytical services.

Dr. Fast joins the company from Pfizer Global R&D, where he served as director of regulated bioanalytical research in Pharmacokinetics, Dynamics and Metabolism. As a member of the Pfizer leadership team, he provided bioanalytical support for nonclinical and first-in-human studies. Dr. Fast also led a global process harmonization team for GLP assay work across sites in the US, UK, and Japan.

In addition to his technical expertise and mass spectrometry experience, Dr. Fast is an expert on bioanalysis regulatory guidelines. He was a key contributor to the creation and publication of the Crystal City Guidelines for Incurred Sample Reanalysis (ISR). Dr Fast currently serves as chair of the Regulated Bioanalysis Workshop of the 2010 Applied Pharmaceutical Analysis Conference.

“Doug’s proven experience in drug development, bioanalysis, and knowledge of regulatory guidance will be an asset to the Covance team and our client partners,” said Steven Michael, vice president and chief scientific officer, global bioanalytical services, Covance.